Kenvue Q2 Sales Miss, But Profit Beats; Acetaminophen Appeals Revived
KVUE sits 38% above its 52-week low of $14.02.
Summary
Kenvue's Q2 sales slightly missed estimates, but profit beat. Revived Tylenol and phenylephrine litigation adds uncertainty ahead of the Kimberly-Clark merger close.
Key Events · Earnings and Guidance · KVUE
-
Q2 Sales Miss, Profit Beat
Net sales of $3.96B missed the $3.97B consensus by 0.3%, while adjusted EPS of $0.31 rose 7% YoY, beating estimates. Organic sales grew 1.6%, driven by Skin Health and Beauty.
-
Acetaminophen Litigation Revived
The Second Circuit vacated a lower court's dismissal of hundreds of lawsuits alleging prenatal Tylenol exposure causes autism, remanding for further proceedings. Kenvue cannot estimate potential liability.
-
Phenylephrine Suits Partially Reinstated
A separate appeals court revived parts of a multi-district litigation over phenylephrine effectiveness, adding to legal overhang. Securities and derivative suits related to PE disclosures remain pending.
-
Merger with Kimberly-Clark Still Pending
The $37.8B stock-and-cash merger, announced November 2025, awaits foreign regulatory approvals. Expected close remains Q4 2026. Kenvue incurred $32M in transaction costs YTD.
Analysis · KVUE · Life Sciences
Kenvue's Q2 sales of $3.96B narrowly missed the $3.97B consensus, but adjusted EPS of $0.31 beat estimates. The quarter was overshadowed by revived litigation risk: a federal appeals court reinstated hundreds of lawsuits alleging prenatal Tylenol exposure causes autism, and similar phenylephrine suits were partially revived. The pending Kimberly-Clark merger remains on track for Q4 close, but foreign regulatory approvals are still outstanding. Restructuring charges continue to weigh on margins, with $147M incurred YTD under the new 2026 plan.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.4% of the 1637 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KVUE was trading at $19.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $37.8B. The 52-week trading range was $14.02 to $22.22. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.